Want to join the conversation?
$BDX 3Q15 Call: Pricing was about flat on a legacy BD basis. YTD pricing is better than our expectations,& as such we are revising our full year guidance for pricing to be about flat YoverY. BD Medical third quarter revenues increased 1.6%. Underlying medical revenue growth was approx. 4%, which includes normalizing for tough comparison in Infusion
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?